Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib.

Begg M, Wilson R, Hamblin JN, Montembault M, Green J, Deans A, Amour A, Worsley S, Fantom K, Cui Y, Dear G, Ahmad S, Kielkowska A, Clark J, Boyce M, Cahn A, Hessel EM.

J Pharmacol Exp Ther. 2019 Jun;369(3):337-344. doi: 10.1124/jpet.118.255109. Epub 2019 Mar 18.


A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.

Khindri S, Cahn A, Begg M, Montembault M, Leemereise C, Cui Y, Hogg A, Wajdner H, Yang S, Robertson J, Hamblin JN, Ludwig-Sengpiel A, Kornmann O, Hessel EM.

J Pharmacol Exp Ther. 2018 Dec;367(3):405-413. doi: 10.1124/jpet.118.249516. Epub 2018 Sep 14.


Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects.

Wilson R, Jarvis E, Montembault M, Hamblin JN, Hessel EM, Cahn A.

Clin Ther. 2018 Aug;40(8):1410-1417. doi: 10.1016/j.clinthera.2018.06.011. Epub 2018 Jul 25.


Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.

Cahn A, Hamblin JN, Begg M, Wilson R, Dunsire L, Sriskantharajah S, Montembault M, Leemereise CN, Galinanes-Garcia L, Watz H, Kirsten AM, Fuhr R, Hessel EM.

Pulm Pharmacol Ther. 2017 Oct;46:69-77. doi: 10.1016/j.pupt.2017.08.008. Epub 2017 Aug 17.


Systemic Exposures of Fluticasone Propionate and Salmeterol Following Inhalation via Metered Dose Inhaler with the Mini Spacer Compared with the Aerochamber Plus Spacer.

Mehta R, Montembault M, Warren F, Gupta A, Brealey N, Moore A.

J Aerosol Med Pulm Drug Deliv. 2016 Aug;29(4):386-92. doi: 10.1089/jamp.2015.1236. Epub 2016 Jan 29.


A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor.

Montembault M, Vo-Thanh G, Deyine A, Fargeas V, Villiéras M, Adjou A, Dubreuil D, Esquieu D, Grégoire C, Opi S, Péloponèse JM, Campbell G, Watkins J, de Mareuil J, Aubertin AM, Bailly C, Loret E, Lebreton J.

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1543-6.


Supplemental Content

Loading ...
Support Center